Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1996-10-22
1999-05-25
Hutzell, Paula K.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 2, 514 26, 424 941, A61K 3843
Patent
active
059069767
ABSTRACT:
A pharmaceutical composition and method for treating injury to or diseases which result in neuronal degeneration resulting from stroke, brain, retina or spinal cord injuries and other brain disorders and possible trauma associated with neurosurgical procedures is disclosed. The composition consists of glutamine synthetase (GS), analogues and derivatives thereof and a pharmaceutical carrier which when administered to a patient prevents or reduces neuronal degeneration.
REFERENCES:
patent: 4439196 (1984-03-01), Higuchi
patent: 4447224 (1984-05-01), DeCant, Jr. et al.
patent: 4447233 (1984-05-01), Mayfield
patent: 4475196 (1984-10-01), La Zor
patent: 4486194 (1984-12-01), Ferrara
patent: 4487603 (1984-12-01), Harris
patent: 4554271 (1985-11-01), Braughler et al.
patent: 4866042 (1989-09-01), Neuwelt
patent: 4959217 (1990-09-01), Sanders et al.
patent: 5013558 (1991-05-01), Konishi
patent: 5135956 (1992-08-01), Borg et al.
patent: 5162375 (1992-11-01), Nichlson et al.
patent: 5167616 (1992-12-01), Haak et al.
patent: 5169383 (1992-12-01), Gyory et al.
patent: 5225182 (1993-07-01), Sharma
patent: 5395822 (1995-03-01), Izumi et al.
patent: 5428069 (1995-06-01), Skolnick et al.
patent: 5444095 (1995-08-01), Tatton et al.
patent: 5455044 (1995-10-01), Kim et al.
patent: 5464764 (1995-11-01), Capecchi et al.
patent: 5487992 (1996-01-01), Capecchi et al.
patent: 5558852 (1996-09-01), Bigner et al.
Gorovits, et al. "Glutamine synthetase protects against neuronal degeneration in injured retinal tissue" Proc. Natl. Acad. Sci. USA, vol. 94, pp. 7024-7029 (1997).
Jackowski, Andre, "Neural injury repair: hope for the future as barriers to effective CNS regeneration become clearer" British Journal of Neurosurgery, 9, 303-317 (1995).
Stull, et al. "Antigene, Ribozyme and Aptamer Nucleic Acid Drugs: Progress and Prospects" Pharmaceutical Research, vol. 12, No. 4 (1995).
Ankarcrona et al., "Glutamate-induced neuronal death: a succession of necrosis or apoptosis depending on mitochondrial function" Neuron, 15:961-973 (1995).
Ben Dror et al., "Developmental control of glucocorticoid receptor transcriptional activity in embryonic retina" Proc. Natl. Acad. Sci. USA, 90:1117-1121 (1993).
Betz et al., in Basis Neurochem. Molecular Cell, Raven Press Ltd., NY 5th edition, pp. 681-699 (1994).
Berko Flint et al., "Involvement of c-Jun in the control of glucocorticoid receptor transcriptional activity . . . " EMBO J., 13:646-654 (1994).
Bickel et al., "Pharmacologic effects in vivo in brain by vector-mediated peptide drug delivery" Proc. Natl. Acad. Sci. USA. 90(7):2618-2622 (1993).
Bonfoco et al., "Apoptosis and necrosis: two distinct events induced, respectively, by mild and intense insults . . . " Proc. Natl. Acad. Sci. USA, 92:7162-7166 (1995).
Bracken et al., "A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal-cord injury . . . " N. Engl. J. Med., 322:1405-1411 (1990).
Braughler et al., "Evaluation of an intensive methylprednisilone sodium succinate dosing regimen in experimental spinal cord injury" J. Neurosurg., 67:102-105 (1987).
Brem et al., "Polymers as controlled drug delivery devised for the treatment of malignant brain tumors" Eur. J. Pharm. Biopharm, 39:2-7 (1993).
Brune et al., "Spermine prevents endonuclease activation and apoptosis in thymocytes" Exp. Cell Res., 195:323-329 (1991).
Calne et al., "Alzheimer's disease, Parkinson's disease, and motoneurone disease: abiotrophic interaction . . . " Lancet, 2:1067-1070 (1986).
Choi, "Glutamate neurotoxicity and diseases of the nervous system" Neuron, 1:623-634 (1988).
Choi, "Calcium: still center-stage in hypoxic-ischemic neuronal death" Trends Neurosci., 18:58-60 (1995).
Choi and Rothman, "The role of glutamate neurotoxicity in hypoxic-ischemic neuronal death" Annu. Rev. Neurosci., 13:171-182 (1990).
Clifford et al., "Ketamine and MK-801 prevent degeneration of thalamic neurons injured by focal cortical seizures" Exp. Neurol., 105:272-279 (1989).
Coyle and Schwarz, "Lesion of striatal neurons with kainic acid provides a model for Huntington's chorea" Nature, 263:244-246 (1976).
David et al., "Involvement of excitatory neurotransmitters in the damage produced in chick embryo retinas . . . " Exp. Eye Res., 46:657-662 (1988).
Drejer et al., "Cellular origin of ischemia-induced glutamate release from brain tissue in vivo and in vitro" J. Neurochem., 45:145-151 (1985).
Dubinsky and Rothman, "Intracellular calcium concentrations during "chemical hypoxia" and excitotoxic neuronal injury" J. Neurosci., 11:2545-2551 (1991).
Dykens et al., "Mechanism of kainate toxicity to cerebellar neurons in vitro is analagous to reperfusion tissue injury" J. Neurochem., 49:1222-1228 (1987).
Gibbs et al., "Sequence of a human glutamine synthetase cDNA" Nucleic Acid Res., 15:6293 (1987).
Gilboa et al., "Transfer and expression of cloned genes using retroviral vectors" BioTechniques, 4(6):504-512 (1986).
Gorovits et al., "Developmental changes in the expression and compartmentalization of theglucocorticoid receptor . . . " Proc. Natl. Acad. Sci. USA, 91:4786-4790 (1994).
Grossman et al., "Molecular basis for differential expression of glutamine synthetase in retina glia and neurons" Brain Res. Mol. Brain Res., 21:312-320 (1994).
Gunnersen and Haley, "Detection of glutamine synthetase in the cerebrospinal fluid of Alzhemier diseased patients . . . " Proc. Natl. Acad. Sci. USA, 89:11949-11953 (1992).
Hall, "High-dose glucocorticoid treatment improves neurological recovery in head-injured mice" J. Neurosurg., 62:882-887 (1985).
Heron et al., "Regional variability in DNA fragmentation after global ischemia evidenced by combined histological and gel . . . " J. Neurochem., 61:1973-1976 (1993).
Koh and Choi, "Quantitative determination of glutamate mediated cortical neuronal injury in cell culture by lactate . . . " J. Neurosci. Methods., 20:83-90 (1987).
Kramer et al., "Gene transfer through the blood-nerve barrier: NGF-engineered neuritogenic T lymphocytes . . . " Nature Medicine, 1:1162-1166 (1995).
Kure et al., "Glutamate triggers internucleosomal DNA cleavage in neuronal cells" Biochem. Biophys. Res. Commun., 179, 39-45 (1991).
Linnik et al., "Evidence supporting a role for programmed cell death in focal cerbral ischemia in rats" Stroke, 24:2002-2009 (1993).
Linser and Moscona, "Induction of glutamine synthetase in embryonic neural retina: localization in Muller fibers and dependence . . . " Proc. Natl. Acad. Sci. USA, 76:6476-6480 (1979).
Linser and Moscona, "Hormonal induction of glutamine synthetase in cultures of embryonic retina cells: requirement for neuron-glia . . . " Dev. Biol., 96:529-534 (1983).
Louzada, Jr. et al., "Glutamate release in experimental ischaemia of the retina: an approach using microdialysis" J. Neurochem., 59:358-363 (1992).
Macmanus et al., "Global ischemia can caused DNA fragmentation indicative of apoptosis in rat brain" Neurosci. Lett., 164:89-62 (1993).
Maragos et al., "Glutamate dysfunction in Alzehimer's disease: an hypothesis" TINS, 10:65-68 (1987).
Mattson, "Excitory amino acids, growth factors and calcium: a teeter-totter model for neural plasticity and degeneration" Adv. Exp. Med. Biol., 268:211-220 (1990a).
Mattson, "Antigenic changes similar to those seen neurofibrillary tangles are elicited by glutamate and Ca2+ influx . . . " Neuron, 4:105-117 (1990b).
Meister, in Biochemical Modulation of Anticancer: Experimental and Clinical Approaches, eds. Valeriote, F.A. and Baker, L.H. Martinus Nijhoff Pub., Boston . . . , pp. 245-259 (1989).
Michaels and Rothman, "Glutamate neurotoxicity in vitro: antagonist pharmacology and intracellular calcium concentrations" J. Neurosci., 10:283-292 (1990).
Moscona, in Progress in Retinal Research, eds. Osborne, N.N. and Chader, G.J., Permagon Press, Oxford, 2:111-135 (1983).
Moscona et al., "Enzyme induction in embryonic retina: the role of transcription and translation" PNAS (USA), 61:160-167 (1968).
Mosinger et al., "Blockade of both NMDA and non-NMDA receptors is required for optimal protection against ischmeic neuronal . . . " Exp. Neurol., 113:10-17 (
Hayes Robert C.
Hutzell Paula K.
Ramot-University Authority for Applied Research and Industrial
LandOfFree
Method and composition for treating neuronal degeneration does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method and composition for treating neuronal degeneration, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method and composition for treating neuronal degeneration will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-401358